Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

11.07.2022

1 Am J Obstet Gynecol
1 BMC Cancer
1 Br J Cancer
1 Clin Cancer Res
1 Gynecol Oncol
1 Hum Pathol
1 Int J Cancer
1 Lancet Oncol



    Am J Obstet Gynecol

  1. MAI PL, Miller A, Black A, Falk RT, et al
    Effect of Risk-Reducing Salpingo-Oophorectomy on Sex-Steroid Hormone Serum Levels among Post-Menopausal Women: An NRG Oncology/GOG Study.
    Am J Obstet Gynecol. 2022 Feb 22. pii: S0002-9378(22)00124.
    >> Share


    BMC Cancer

  2. KENNEDY F, Shearsmith L, Holmes M, Rogers Z, et al
    Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.
    BMC Cancer. 2022;22:726.
    >> Share


    Br J Cancer

  3. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
    Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
    >> Share


    Clin Cancer Res

  4. CHENG Z, Mirza H, Ennis DP, Smith P, et al
    The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
    >> Share


    Gynecol Oncol

  5. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    >> Share


    Hum Pathol

  6. LONDERO AP, Orsaria M, Viola L, Marzinotto S, et al
    Survivin, Sonic hedgehog, Kruppel-like factors, and p53 pathway in serous ovarian cancer: an immunohistochemical study.
    Hum Pathol. 2022 Jun 28. pii: S0046-8177(22)00168.
    >> Share


    Int J Cancer

  7. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    >> Share


    Lancet Oncol

  8. CLAMP AR, James EC, McNeish IA, Dean A, et al
    Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2022;23:919-930.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016